Estrella Immunopharma amends clinical trial service agreement with Eureka to clarify termination payment terms

Estrella Immunopharma, Inc.

Amendment No. 1 to SOW #001 for EB103 anti-CD19 ARTEMIS® clinical trial clarifies pay-on-termination obligations.
Upon termination, Estrella pays only for achieved milestones, pass-through costs, and third-party commitments before notice.
Eureka must use commercially reasonable efforts to cancel or reduce such third-party commitments.
Amendment effective March 4, 2024; filed on May 13, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Estrella Immunopharma, Inc. amended Amendment No. 1 to the Statement of Work with Eureka Therapeutics, Inc. (effective 2024-03-04).

Action: amendment
Counterparty: Eureka Therapeutics, Inc.
Effective: 2024-03-04

Exact text from the filing

On May 13, 2024, Estrella Immunopharma, Inc. (the “Company”), Estrella Biopharma, Inc. (“Estrella”), a wholly-owned subsidiary of the Company and the sole operating subsidiary of the Company, and Eureka Therapeutics, Inc. (“Eureka”), the controlling shareholder of the Company, entered into Amendment No. 1 to the Statement of Work (“Amendment No. 1”), effective as of March 4, 2024, which amends Statement of Work #001 (the “SOW”), dated and effective as of March 4, 2024, among the Company, Estrella, and Eureka, relating to the services (“Services”) to be performed by Eureka for Estrella in connection with Estrella’s EB103 anti-CD19 ARTEMIS® clinical trial.

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-042444

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.